Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1206-1210

  Cengel, Keith A ^a   Deutsch, Eric ^a,b   Stephens, Trevor C ^c   Voong, K Ranh ^a   Kao, Gary D ^a   Bernhard, Eric J ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Pancreatic cancer; Prenyltransferase; Radiation; RAS; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 3409; DIMETHYLALLYLTRANSFERASE; GERANYLTRANSFERASE; K RAS PROTEIN; PROTEIN FARNESYLTRANSFERASE; RAS PROTEIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MUTANT; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE RAS; PANCREAS CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; XENOGRAFT;

EID: 33751116803     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3172     Document Type: Article

References (23)

1. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410:1111-6.
2. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002; 1:53-62.
3. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004; 14:105-14.
4. Cengel KA, McKenna WG. Molecular targets for altering radiosensitivity: Lessons from Ras as a preclinical and clinical model. Crit Rev Oncol Hematol 2005; 55:103-16.
5. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005; 1756:127-44.
6. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000; 60:6597-600.
7. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-Ras. Cancer Res 2005; 65:8433-41.
8. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, Birnbaum MJ, Bernhard EJ. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005; 65:7902-10.
9. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65:241-269.
10. Prior IA, Hancock JF. Compartmentalization of Ras proteins. J Cell Sci 2001; 114:1603-1608.
11. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63:5656-68.
12. Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003; 3:945-51.
13. Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000; 1484:93-106.
14. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995; 270:6221-6.
15. Fiordalisi JJ, Johnson IInd RL, Weinbaum CA, Sakabe K, Chen Z, Casey PJ, Cox AD. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. J Biol Chem 2003; 278:41718-27.
16. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. 1997; 15:1283-1288.
17. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to supress human tumor growth in nude mouse xenografts. Oncogene 1998; 16:1467-73.
18. Stephens T, Wardleworth M, Matusiak Z, Ashton S, Hancox U, Bate M, Ferguson R, Boyle T. Proc Am Assoc Cancer Res 2003; 44, (Abs # 4870).
19. McCormack P, Macpherson M, Wilson D, Lindsay A, Parry T, Holt A, Hughes A. Pharmacokinetic characterization of the novel oral prenyl transferase inhibitor AZD3409: The first analysis in healthy male volunteers. Proc ASCO 2004; 22.
20. Smethurst D, Holt A, Parry T, Lindsay A, Wilson D, Hughes A. Tolerability results from the first study of the novel oral prenyl transferase inhibitor AZD3409 in human volunteers. Proc ASCO 2004; 22:3177.
21. Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 1988; 239:645-7.
22. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 2002; 62:4142-50.
23. Grana TM, Sartor CI, Cox AD. Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res 2003; 63:7807-14.